Core Viewpoint - The oral drug VV116, already approved for COVID-19 treatment, shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready option for addressing future outbreaks [1][2][5]. Group 1: Research Findings - VV116 has demonstrated significant antiviral activity against two main strains of the Nipah virus (NiV-M and NiV-B) in vitro [2]. - In animal studies, administering VV116 at a dosage of 400 mg/kg increased the survival rate of infected golden hamsters to 66.7% and significantly reduced viral loads in key organs [4][5]. - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat, with a mortality rate ranging from 32% to 70% [5]. Group 2: Clinical Development and Market Potential - VV116 is a collaborative effort involving multiple research institutions and companies, with clinical development and commercialization responsibilities shared by Junshi Biosciences and Wangshan Wangshui [7]. - The drug has received emergency use authorization in Uzbekistan and conditional approval in China for COVID-19 treatment, indicating its potential for rapid deployment in public health emergencies [7][10]. - Wangshan Wangshui is actively pursuing the development of new indications for VV116, including potential applications for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) [9]. Group 3: Company Responses and Future Directions - Junshi Biosciences has stated that it is not currently conducting research on expanding VV116's indications for Nipah virus treatment, emphasizing the need for clinical data [11]. - In contrast, Wangshan Wangshui has expressed intent to monitor the Nipah virus situation closely and initiate clinical trials as necessary to address public health needs [11]. - The financial performance of Wangshan Wangshui has been impacted by the decline in demand for COVID-19 treatments, with significant losses reported in recent quarters [12].

Core Viewpoint - The oral COVID-19 drug VV116 shows significant antiviral activity against the highly lethal Nipah virus, potentially providing a ready-made treatment option amid the absence of approved vaccines or specific therapies for Nipah virus infections [2][4][7]. Group 1: Research Findings - Recent studies published in the journal "Emerging Microbes & Infections" confirm that VV116 can increase the survival rate of infected golden hamsters to 66.7% and significantly reduce viral loads in key organs [4][6]. - The research indicates that VV116 exhibits notable inhibitory effects against two main strains of the Nipah virus, NiV-M and NiV-B, in vitro and in animal models [6][8]. - The Nipah virus has a mortality rate ranging from 32% to 70%, with recent outbreaks reported in India, raising public health concerns [6][7]. Group 2: Company Responses - Junshi Bioscience stated that they have not conducted similar research and that expanding indications would require clinical data support [2][12]. - In contrast, Wangshan Wangshui expressed their intent to closely monitor the epidemic's developments and initiate clinical trials for treatment or post-exposure prevention as needed [2][12]. Group 3: Market Impact - Following the announcement, Wangshan Wangshui's stock price surged nearly 15% during trading on January 27, closing at 108.9 HKD per share, marking a 10.90% increase and a historical high [3]. - Junshi Bioscience's stock also rose by 7.96% on the same day [3]. Group 4: Broader Implications - VV116, developed through collaboration among several Chinese research institutions, is positioned as a broad-spectrum antiviral drug with potential applications beyond COVID-19, including against other RNA viruses [8][10]. - The drug's mechanism targets the highly conserved RNA-dependent RNA polymerase (RdRp) of RNA viruses, suggesting its effectiveness against future viral variants [8][10]. Group 5: Financial Context - Wangshan Wangshui reported that VV116 generated significant revenue, accounting for 98% of the company's total revenue in 2023, but faces challenges as demand for COVID-19 treatments declines [13]. - The company has experienced financial losses in the post-pandemic era, with net losses of approximately 218 million CNY in 2024 and 112 million CNY in the first four months of 2025 [13].